Pinealon: The Pineal Gland Peptide

Category: Protocols Type: Protocol Read Time: 14 minutes Author: Peptides.NYC Editorial Last Updated: 2026-05-19 URL: https://peptides.nyc/learn/pinealon-protocol

Disclaimer: This content is for educational purposes only and is not medical advice. Pinealon is sold as a dietary supplement in Russia and the CIS region but is not FDA-approved in the United States and exists in a research-chemical / supplement gray area. Always consult a qualified healthcare provider before starting any peptide protocol.

Overview

Pinealon is a short synthetic tripeptide (Glu-Asp-Arg) belonging to the Khavinson family of peptide bioregulators — a class of 2–4 amino acid sequences derived from extracts of specific organ tissues. As the name suggests, Pinealon was developed from active peptide fractions of the pineal gland and is marketed for circadian rhythm, sleep quality, cognitive aging, and general gerontological support.

Unlike most peptides discussed in Western biohacking circles, Pinealon is taken orally in capsule form. The Russian standard dose is 100mg per day for short, intermittent courses, typically run twice a year. Injectable forms exist but are uncommon and not the labeled route of administration.

Pinealon sits at the intersection of two worlds: an extensive but largely Russian-language body of research from the Khavinson laboratory, and a Western community that has cautiously adopted it as part of long-term anti-aging stacks alongside Epithalon, Thymogen, Cortexin, and Cerluten.

Key Properties:

• Tripeptide: Glu-Asp-Arg (EDR)
• Oral capsule administration
• Khavinson "bioregulator" classification
• Short intermittent courses, not continuous use
• Often combined with Epithalon in gerontology stacks

Khavinson Bioregulator Concept

The bioregulator framework was developed primarily by Prof. Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology, with collaborators including Vladimir Anisimov. The central claim is that short peptides — extracted from or synthesized to match sequences found in specific organs — can act as tissue-specific gene regulators, binding to DNA or chromatin and modulating expression patterns associated with healthy function of that tissue.

In the Khavinson model:

• Pinealon targets pineal tissue gene expression
• Thymogen / Thymalin target thymic immune function
• Cortexin targets cortical neurons
• Cerluten targets cerebellar tissue
• Epithalon targets telomerase and pineal/circadian aging

This framework is methodologically controversial in Western literature. Critics note small sample sizes, single-laboratory replication, limited blinding standards by modern RCT criteria, and a proposed mechanism (oral tripeptides reaching the nucleus and binding DNA selectively) that has not been independently confirmed at scale.

At the same time, the Russian clinical literature is substantial — decades of studies, hundreds of papers, and routine clinical use in Russia, Ukraine, and parts of Eastern Europe. The honest summary is: promising and extensively used, but not validated by Western RCT standards.

Mechanism of Action

The proposed mechanisms for Pinealon, drawn primarily from Khavinson-lab publications, include:

1. Gene-regulatory effects in pineal tissue — Pinealon is described as influencing expression of genes related to melatonin synthesis, circadian regulators, and apoptosis control in pineal cells.
2. Indirect circadian normalization — rather than acting as melatonin replacement, Pinealon is positioned as restoring endogenous circadian signaling capacity, particularly in aged tissue.
3. Neuroprotective effects in animal models — published rodent studies report reduced oxidative damage, improved spatial memory, and protection against ischemia-induced neuronal loss.
4. Anti-aging gene expression changes — Khavinson-lab data describe upregulation of pro-survival and downregulation of pro-apoptotic gene patterns in aged tissue cultures.

Important caveat: most mechanistic claims rest on in vitro and small in vivo models from a single research program. Treat the mechanism as a working hypothesis backed by real but narrow evidence, not as established pharmacology.

Dosing Protocols

The "2x per year, 10–20 days" pattern is central to the Khavinson approach. Bioregulators are framed as resetting tissue function rather than continuously stimulating it — analogous to how you would not take a vacation 365 days a year and expect it to remain restorative.

Some practitioners run shorter quarterly mini-courses (e.g., 10 days every 3 months) instead of two longer cycles. Both patterns appear in the literature; neither has been compared head-to-head in rigorous trials.

Pinealon vs Epithalon

These two are the most commonly confused — and most commonly stacked — pineal peptides.

The two are routinely stacked in Russian gerontology protocols — Epithalon for the telomerase/longevity angle, Pinealon for the cognitive and circadian dimension. They are positioned as complementary rather than redundant.

Expected Outcomes

Realistic expectations matter here, because the changes are subjective and gradual:

Weeks 1–3 (during the course):

• Improved sleep quality is the most commonly reported subjective effect
• Slight improvement in time-to-fall-asleep and depth of sleep
• Some users report a calmer evening "wind down"

Weeks 2–4 (mid-to-late course):

• Modest cognitive feel — clarity, mood stability
• These effects are subtle; expect "slightly better baseline," not a stimulant-like surge
• Some users report no clearly perceptible change

Beyond the course:

• Khavinson-lab claims include longer-term gerontological support and age-related decline mitigation
• These long-term effects are inferred from animal and observational data; they are not something an individual user can subjectively verify

If you go in expecting dramatic, easily measurable change, you will likely be disappointed. The framing in Russian gerontology is preventive and cumulative across years, not acute.

Side Effects & Safety

Pinealon is described as exceptionally well-tolerated in the published Khavinson trials and in decades of clinical use as a dietary supplement in Russia and the CIS region. The literature reports:

• No significant adverse events at standard 100mg/day oral dosing
• No reported hormone disruption
• No documented withdrawal or rebound effects
• No notable drug interaction reports (though this reflects limited investigation, not certainty)

Theoretical considerations remain:

• Pregnancy / breastfeeding — not studied; avoid
• Children / adolescents — not studied; avoid
• Active malignancy — caution with any compound proposed to influence gene expression
• Authentic sourcing — the safety profile assumes a real Glu-Asp-Arg tripeptide at labeled dose; counterfeit or mislabeled products carry unknown risk

The safety profile is favorable, but the evidence base is single-program. "Well tolerated in available data" is not the same as "fully characterized."

Combining With Melatonin & Other Sleep Aids

A common question is whether Pinealon replaces melatonin or other sleep tools. The Khavinson framework positions these as acting at different levels of the sleep system, not as substitutes for one another.

These are not antagonistic. A common stack pattern: magnesium nightly, low-dose melatonin as needed, Pinealon during a twice-yearly course, DSIP only for specific architecture issues.

Pinealon is not a hypnotic — do not expect a single capsule to put you to sleep the way a melatonin tablet might.

The Khavinson Stack — Long-Term Anti-Aging Protocol

In Russian gerontology, Pinealon is rarely used in isolation. It is one component of a multi-tissue bioregulator approach:

The classical pattern runs short courses of each across the year — for example, one bioregulator per month on a rotating schedule, or paired courses (Pinealon + Epithalon together in spring, Thymogen + Cortexin in fall). Specific stack design varies by clinic and practitioner.

This is the Russian gerontology approach in concentrated form. Western adoption is partial — many users pick one or two of these (most commonly Epithalon and Pinealon) rather than running the full multi-bioregulator schedule.

Realistic Expectations & Evidence Quality

Honesty about evidence quality matters more for Pinealon than for many other peptides, because the marketing narrative often overstates the case.

What is true:

• The Khavinson program is real, extensive, and decades long
• Pinealon is approved and used as a supplement in Russia and the CIS region
• There is a coherent mechanistic framework with supporting in vitro and animal data
• Side effect reports are minimal

What is also true:

• Most studies are Russian-language and not indexed in major Western databases
• Sample sizes are smaller than modern Western RCT standards
• Replication is mostly within a single research program
• The mechanism (short oral peptides reaching nuclei and binding DNA selectively) is not independently established at scale
• No large, well-blinded, Western-style RCT has confirmed major endpoints

The honest framing: Pinealon is promising-but-not-rigorously-validated by Western standards. It is not snake oil — but it is also not in the same evidence tier as well-studied compounds with multi-center placebo-controlled trials. Use that calibration when deciding whether to include it in a personal protocol.

Cycling

Pinealon is explicitly not designed for continuous daily use. The cycling pattern is part of the protocol.

Standard pattern:

• 10–20 day intensive course
• Twice per year (spring and fall)
• Long off-periods between courses

Alternative quarterly pattern:

• 10 day mini-course
• Every 3 months
• Some practitioners prefer this for steadier exposure

What to avoid:

• Continuous daily use for months — outside the bioregulator framework, no published support
• Doubling dose to "speed up" effects — the protocol assumes 100mg/day; higher is unstudied
• Stacking with every other Khavinson peptide simultaneously without rotation

Cycling is not just a safety convention here; it is part of how the compound is supposed to work according to its own theoretical model.

Frequently Asked Questions

Q: Is Pinealon just a fancy melatonin replacement? A: No. Melatonin is a hormone you supplement directly; Pinealon is positioned as a gene-level support for the tissue that makes melatonin. They operate at different levels and are often used together rather than as substitutes.

Q: Does the gene-regulation mechanism actually work? A: The Khavinson lab has published data supporting it, but the mechanism has not been independently confirmed at scale by Western research groups. Treat it as a plausible working hypothesis with internal evidence, not as established pharmacology.

Q: Can I stack Pinealon with Epithalon? A: This is one of the most common Russian gerontology pairings. Pinealon (oral, cognitive/circadian) and Epithalon (injectable, telomerase) are positioned as complementary rather than redundant.

Q: How do I source authentic Pinealon? A: Authentic Khavinson-line bioregulators originate from a small number of Russian manufacturers. Third-party COA verification of the Glu-Asp-Arg sequence and purity is the minimum standard. Be skeptical of unusually cheap product or unbranded capsules with no chain of supply.

Q: Does an oral tripeptide really survive digestion? A: This is one of the legitimate scientific questions. The Khavinson program argues that small peptides (2–4 amino acids) cross the gut wall intact in sufficient quantity to act. Independent confirmation outside that program is limited.

Q: How credible is the Khavinson research? A: It exists, it is extensive, and it is internally consistent. It is also single-program, mostly Russian-language, and not held to modern multi-center Western RCT standards. Both "it's real research" and "it's not rigorously validated by Western standards" are simultaneously true.

Q: Will I feel it the first day? A: Unlikely. Most users report subtle changes — better sleep quality, calmer evenings, slightly clearer mornings — emerging across the first one to three weeks of a course.

Q: Is Pinealon legal in the US? A: Pinealon is not FDA-approved as a drug or supplement in the United States. It is sold as a dietary supplement in Russia and the CIS region. In the US it exists in a research-chemical / supplement gray area. Check your local jurisdiction.

Related Content

• Epithalon Protocol
• DSIP Protocol
• Cerebrolysin Protocol
• Cognitive Peptide Stack
• Beginner's Stack Guide

Disclaimer: This content is for educational purposes only and is not medical advice. Pinealon is not FDA-approved for human use in the United States. Khavinson bioregulator research is real and extensive but does not meet Western RCT standards of validation. Consult a qualified healthcare provider before starting any peptide protocol.

Source: https://peptides.nyc/learn/pinealon-protocol